Our results showed a significant heterogeneity among the 5 case-control studies (I2 = 56%), and revealed that hypermethylation of CDKN2B gene was associated with the increased risk of leukemia (P = 0.001, OR = 9.67, 95% CI = 2.48–37.75). This evidence concerns the gene CDKN2B and leukemia.